Publications by authors named "Noboru Chida"

Claim this Profile
D
Discovery of 2,4-diamino-5-cyanopyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions.
Shigeki Kunikawa, Akira Tanaka, Yuji Takasuna, Mamoru Tasaki, Noboru Chida

Bioorg Med Chem· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model.
Shigeki Kunikawa, Akira Tanaka, Yuji Takasuna, Mamoru Tasaki, Noboru Chida

Bioorg Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
Shunsuke Maehara, Keita Arakawa, Kotaro Hoshida, Hiroshi Nagasue, Noboru Chida

Eur J Pharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Misato Ito, Shunji Yamazaki, Kaoru Yamagami, Masako Kuno, Yoshiaki Morita, Noboru Chida

J Pharmacol Sci· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of novel PKCθ selective inhibitor AS2521780 on acute rejection in rat and non-human primate models of transplantation.
Hidehiko Fukahori, Noboru Chida, Masashi Maeda, Mamoru Tasaki, Tomoko Kawashima

Int Immunopharmacol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability.
Shigeki Kunikawa, Akira Tanaka, Koichiro Mukoyoshi, Shinya Nagashima, Hiroaki Tominaga, Noboru Chida

Bioorg Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of AS2521780, a novel PKCθ selective inhibitor, on T cell-mediated immunity.
Hidehiko Fukahori, Noboru Chida, Masashi Maeda, Mamoru Tasaki, Tomoko Kawashima

Eur J Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a novel inducible nitric oxide synthase inhibitor, FR260330, in prevention of renal ischemia/reperfusion injury in vervet monkeys.
Shijie Qi, Dasheng Xu, Anlun Ma, Xiaochun Zhang, Noboru Chida

Transplantation· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel inhibitor of vacuolar ATPase, FR202126, prevents alveolar bone destruction in experimental periodontitis in rats.
Kazuaki Niikura, Nobuaki Takeshita, Noboru Chida

J Toxicol Sci· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections.
Jun Ouyang, Dasheng Xu, Xiaochun Zhang, Shijie Qi, Anlun Ma, Noboru Chida

Transplantation· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor.
Noboru Chida, Yoshimi Hirasawa, Takehiko Ohkawa, Yoshinori Ishii, Yuji Sudo

Eur J Pharmacol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis